No abstract

, FÁTIMA AZEVEDO IGNÁCIO 7 , ROGÉRIO PAYSANO MARROCOS 8 ABSTRACT -We tested the hypothesis that Part B of the Trail Making Test (TMT) is a measure of cognitive setshifting ability in 55 normal subjects with the conventional (written) TMT and a verbal adaptation, the "verbal TMT" (vTMT). The finding of a significant association between Parts B of TMT and vTMT (r = 0,59, p < 0,001), after correcting for age and education, supports the view that Part B of TMT is a valid measure of the ability to alternate between cognitive categories.KEY WORDS: trail making test, verbal trail making test, set-shifting cognition. . In Part A, the circles are numbered from 1 to 25, whereas in Part B numbers from 1 to 13 and letters from A to M must be connected in alternating fashion, beginning at 1-A and ending at M-13. Total score is given by time spent to complete each part. Factor analysis has shown that the TMT loads on both a rapid visual search and a visuospatial sequencing factor 3 . Whether it also superimposes on a third, "cognitive set-shifting", factor has been debated [4][5][6] . If true, however, this would be an important attribute of the test, as the ability to switch between categories is one of the most reliable indexes of normal neurobehavioral functioning 7 .In this study we administered a verbal adaptation of TMT-the "verbal Trail Making Test" (vTMT)-to normal individuals to see whether Part B of Trail Making Test (TMTB) also gauges the ability to shift between cognitive sets. Since in vTMT the visuospatial and visuomotor factors intrinsic to the conventional (written) TMT are reduced to a minimum, a lack of correlation between Parts B

No abstract

No abstract

Dementia with Lewy bodies (DLB) is commonly associated with excessive daytime somnolence (EDS). Modafinil is a wakefulness-promoting agent that is considered to have limited interaction with the dopaminergic system. As individuals with DLB are predisposed to psychotic symptoms which might be exacerbated by dopaminergic stimulation, modafinil is considered to be an attractive option for the treatment of EDS in DLB. We describe two cases in which administration of modafinil exacerbated agitation and hallucinations in DLB, and we also review data that may explain the mechanisms underlying this effect. In both cases, psychotic symptoms emerged concomitantly with modafinil administration, and remitted following its discontinuation. Although definitive data regarding the benefits and adverse effects of modafinil for the treatment of EDS in DLB await controlled prospective randomized studies, our observations warrant caution regarding its use in this context.

SUMMARY -The present paper reports the long-term use of clozapine in a prospective sample of 46 chronic schizophrenics. In six months, 21 subjects had been excluded for a number of reasons. In four of them the reasons for exclusion were related to lack of response or adverse effects. The median daily clozapine dose was 400 mg in the remaining 25 patients. As a whole, there were remarkable improvements in core dimensions of psychopathology, global cognitive status, and level of functioning. We confirmed that clozapine is effective in a subgroup of schizophrenics with the severest forms of the disease. If tolerated after the first few months it leads to progressive gains in several domains of behavior. Clozapine should be tried in every patient with schizophrenia in whom positive symptoms, disorganization, or bizarre behavior are a matter of incapacitation despite efforts to keep them under control with other drugs.KEY WORDS: clozapine, schizophrenia, psychosis, psychopathology. Clozapina na esquizofrenia grave: melhora duradoura e sustentadaRESUMO -O presente estudo, prospectivo, relata o uso de longo-prazo da clozapina em 46 esquizofrênicos graves, com mais de cinco anos de doença. Com seis meses de uso da droga, 21 indivíduos haviam sido excluídos por diversas razões. Em quatro, a exclusão se deveu a efeitos adversos ou ausência de resposta. A dose mediana de clozapina foi de 400 mg nos demais 25 pacientes. No todo, observamos melhora em dimensões de psicopatologia, estado cognitivo global, e nível funcional. Concluímos que a clozapina é eficaz em um subgrupo de esquizofrênicos com formas graves da doença. Se tolerada depois dos primeiros meses, produz benefícios progressivos em diversos domínios do comportamento. Clozapina deve ser tentada em todo paciente com esquizofrenia incapacitado por sintomas positivos, desorganização, e/ou comportamentos bizarros, que persistem a despeito de esforços para mantê-los sob controle com outras drogas.

Cases of “adolescent insanity” were known to Kraepelin’s forerunners and lay at the core of his concept of dementia præcox. In the post-neuroleptic era it became clear that dementia may also occur in schizophrenia as a fully reversible state depending on psychopathological status. In the present review we discuss the validity of applying the concept of dementia to schizophrenia. We concur with the view that schizophrenia may lead to a true dementia both (i) as a fixed end-stage consequence of the disease process itself, or (ii) as a drug-responsive reversible state. There is an urgent need to examine the patterns of dementia in other common neuropsychiatric disorders, employing current methods of neurobehavioral investigation.

The atypical form of Pantothenate Kinase-Associated Neurodegeneration (PKAN) tends to present at around the age of 14 years, has a heterogeneous presentation with extrapyramidal symptoms, and approximately one third of patients exhibit psychiatric problems. This paper reports the case of a patient with apparent typical symptoms of Tourette syndrome. However, the severity and poor response to treatment led to further investigation and the diagnosis of PKAN as a secondary cause of Tourettism was reached.